Cargando…

Pharmacokinetics–pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients

Antimicrobials are among the most important and commonly prescribed drugs in the management of critically ill patients and beta-lactams are the most common antibiotic class used. Critically ill patient’s pathophysiological factors lead to altered pharmacokinetics and pharmacodynamics of beta-lactams...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veiga, Rui Pedro, Paiva, José-Artur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151903/ https://www.ncbi.nlm.nih.gov/pubmed/30244674 http://dx.doi.org/10.1186/s13054-018-2155-1

Ejemplares similares

Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams
por: Gonçalves-Pereira, Joao, et al.
Publicado: (2011)

Beta-lactam antibiotics in continuous infusion in critically ill patients
por: Jeurissen, Axel, et al.
Publicado: (2010)

Pharmacokinetics and pharmacodynamics of antibiotics in critically ill acute kidney injury patients
por: Zamoner, Welder, et al.
Publicado: (2016)

Catecholamine pharmacokinetics and pharmacodynamics in critical illness
por: Johnston, AJ, et al.
Publicado: (2003)

Pharmacodynamic Thresholds for Beta-Lactam Antibiotics: A Story of Mouse Versus Man
por: Berry, Angela V., et al.
Publicado: (2022)

Editorial: Antibiotics Special Issue on Pharmacokinetic/Pharmacodynamic Models of Antibiotics
por: Kebriaei, Razieh, et al.
Publicado: (2022)

Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?
por: Van Herendael, Bruno, et al.
Publicado: (2012)

Importance of beta-lactam pharmacokinetics and pharmacodynamics on the recovery of microbial diversity in the airway of persons with cystic fibrosis
por: Hahn, Andrea, et al.
Publicado: (2021)

Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients
por: Han, Ruiying, et al.
Publicado: (2021)

Clinical Relevance of Antibiotic Susceptibility Profiles for Screening Gram-negative Microorganisms Resistant to Beta-Lactam Antibiotics
por: Montiel-Riquelme, Francisco, et al.
Publicado: (2020)

Time Above All Else: Pharmacodynamic Analysis of Β-Lactams in Critically Ill Patients
por: Landmesser, Katherine, et al.
Publicado: (2021)

Continuous beta-lactam infusion in critically ill patients: the clinical evidence
por: Abdul-Aziz, Mohd H, et al.
Publicado: (2012)

Update on Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Critically Ill Patients—A Narrative Review
por: Stašek, Jan, et al.
Publicado: (2023)

Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review
por: Sime, Fekade Bruck, et al.
Publicado: (2012)

1316. Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol in Critically Ill Patients
por: Katsube, Takayuki, et al.
Publicado: (2020)

Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients
por: Roberts, Jason A, et al.
Publicado: (2011)

Beta-Lactam Antibiotic Therapeutic Drug Monitoring in Critically Ill Patients: A Systematic Review and Meta-Analysis
por: Pai Mangalore, Rekha, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Dosage Individualization of Suppressive Beta-Lactam Therapy Administered by Subcutaneous Route in Patients With Prosthetic Joint Infection
por: Goutelle, Sylvain, et al.
Publicado: (2021)

Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial
por: Ewoldt, Tim M. J., et al.
Publicado: (2022)

The clinical application of beta-lactam antibiotic therapeutic drug monitoring in the critical care setting
por: Pai Mangalore, Rekha, et al.
Publicado: (2023)

THE BETA-LACTAM ANTIBIOTICS: Penicillins and Cephalosporins in Perspective
Publicado: (1980)

Use of beta-lactams antibiotics in ICU patients
por: Damas, M-P, et al.
Publicado: (2015)

Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients
por: Maseda, Emilio, et al.
Publicado: (2018)

Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study
por: Ewoldt, Tim M. J., et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation
por: Bakdach, Dana, et al.
Publicado: (2022)

A Critical Review of the Pharmacokinetics, Pharmacodynamics, and Safety Data of Antibiotics in Avian Species
por: Soh, Hui Yun, et al.
Publicado: (2022)

Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients
por: Barbier, François, et al.
Publicado: (2023)

Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics
por: Zmarlicka, Monika T, et al.
Publicado: (2015)

Beta-lactam antibiotic test doses in the emergency department
por: Maguire, Michelle, et al.
Publicado: (2020)

Suspected allergy to Beta-Lactam antibiotics: An infectiological perspective
por: Sunderkötter, Cord
Publicado: (2022)

Cephalosporins as key lead generation beta-lactam antibiotics
por: Lin, Xuemei, et al.
Publicado: (2022)

Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy
por: Ulldemolins, Marta, et al.
Publicado: (2014)

The Current Status and Future Perspectives of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients
por: Novy, Emmanuel, et al.
Publicado: (2023)

Evaluation of pharmacokinetic and pharmacodynamic parameters of meropenem in critically ill patients with acute kidney disease
por: Hassanpour, Rezvan, et al.
Publicado: (2021)

Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT)
por: Abdulla, Alan, et al.
Publicado: (2020)

Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38
por: Mathijssen, R H J, et al.
Publicado: (2002)

The Pharmacokinetics of Beta-Lactam Antibiotics Using Scavenged Samples in Pediatric Intensive Care Patients: The EXPAT Kids Study Protocol
por: Schouwenburg, Stef, et al.
Publicado: (2021)

Identifying “at-risk” patients for sub-optimal beta-lactam exposure in critically ill patients with severe infections
por: Abdul-Aziz, Mohd H., et al.
Publicado: (2017)

Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?
por: Barreto, Erin F., et al.
Publicado: (2021)

Effect of Beta-Lactam Antibiotics on Microspore Embryogenesis in Brassica Species
por: Mineykina, Anna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kvi8c93b0vcp1bt5o2o89oq0s3